Immunic announces that vidofludimus calcium acts as potent nurr1 activator, reinforcing neuroprotective potential in multiple sclerosis

– preclinical data published in the peer-reviewed journal of medicinal chemistry identifies vidofludimus calcium as a potent nurr1 activator – – nurr1 activation suggested to prevent neurodegeneration which is relevant in multiple sclerosis, parkinson's disease and beyond – new york , may 17, 2023 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the publication of preclinical data confirming that vidofludimus calcium (imu-838) acts as a potent nuclear receptor related 1 (nurr1) activator, in addition to its known mode of action as a dihydroorotate dehydrogenase (dhodh) inhibitor. activation of nurr1 could be responsible for the drug's postulated neuroprotective effects and may contribute to the previously reported reduction of confirmed disability worsening events in multiple sclerosis patients.
IMUX Ratings Summary
IMUX Quant Ranking